Florida Department of Health issued Executive Order 20-006 which allows for COVID-19 Testing by Pharmacists. This order suspends the provision of Section 418.813 of the Florida Statutes that requires a pharmacist to be separately licensed to perform a clinical laboratory tests and also suspends the provision of Section 465.003 (13) of the Florida Statutes that may prohibit a pharmacist from ordering, administering, or reporting the results of COVID-19 tests, including serology tests, authorized by the FDA at a location with a clear and active pharmacy license.   

Also in Florida… the Agency for Health Care Administration has issued an ALERT to provide Florida Medicaid coverage updates of laboratory testing for COVID-19.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

H.B. 389, sponsored by Representative Tyler Sirois (R) in the House and Senator Travis Hutson (R) in the Senate, was signed by Governor Ron DeSantis (R) on March 11, 2020 and becomes effective July 1, 20202. This measure authorizes pharmacists to test for and treat influenza and streptococcus. This bill also authorizes collaborative pharmacy practice agreements between pharmacist and physician in certain circumstances; requires agreements to be appropriate to training & scope of practice of pharmacist and physician; requires maintenance of records & specified pharmacists to report certain diseases of public health significance to DOH and provides requirements for written protocol between pharmacist and supervising physician.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

Senate Bil 714, testing for and treatment of influenza and streptococcus, was amended to remove streptococcus, heard and passed out favorably from the Senate Health Policy Subcommittee with a vote of 6-3 on February 19th. The next stop is the Senate Appropriations Subcommittee on Health and Human Services.  NACDS had previously written a letter in support of the bill. 

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

Florida House Bill 389 Testing for and Treatment of Influenza and Streptococcus was heard on January 15th in the House Health Care Appropriation Subcommittee. The bill passed favorably with a vote of 10-1. The next stop is the House Health and Human Services.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

HB 389, Testing for and Treatment of Influenza and Streptococcus, was heard on November 13 in the House Health Quality Subcommittee. The bill passed favorably with a vote of 11-3, next stop is the House Health Care Appropriations Committee.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

HB 389, Testing for and Treatment of Influenza and Streptococcus, was heard on November 13 in the House Health Quality Subcommittee. The bill passed favorably with a vote of 11-3, next stop is the House Health Care Appropriations Committee.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

Effective Tuesday, October 1, IngenioRx, Inc. (IngenioRx) will begin to administer the prescription benefits for Simply Healthcare of Florida Inc. (Simply) Comprehensive Plan and Clear Health Alliance Specialty Plans. Members may be transitioned to a network pharmacy with IngenioRx that continues to meet member access requirements.

Providers that are out of network as of Tuesday, October 1 will be eligible for a 60-day continuity of care period where claims will be payable to allow time for members to transition to a new pharmacy, if necessary. All members were notified of this transition by mail on August 2. The continuity of care period ends on Saturday, November 30.

The pharmacy claim processing information to IngenioRx for Simply Comprehensive Plan and Clear Health Alliance Specialty Plan is noted below:

RXBIN:   020107
RXPCN:   CH
RXGRP:   WK3A
Member ID Format: 11-14 digits

For questions regarding future network or contract related inquiries, call IngenioRx at 1-833-235-2030.

Prior to Tuesday, October 1, providers may contact Simply Provider Services for eligibility or prior authorization questions at 1-877-577-9044.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.